RESUMO
INTRODUCTION: Cardiometabolic management was evaluated in patients with diabetes and a severe mental illness that require treatment with an atypical antipsychotic. METHODS: Seventy-four patients with diabetes and a severe mental illness treated with an atypical antipsychotic from the Fargo Veterans' Affairs Health Care System were included in this retrospective study. Primary end points analyzed the change in hemoglobin A1c (Hgb A1c), blood pressure, and low-density lipoprotein (LDL) cholesterol 12 months prior to and 12 months following the initiation of an atypical antipsychotic. Secondary end points evaluated changes specific to clozapine and olanzapine. Additional secondary end points evaluated the medication management for cardiometabolic disease prior to and following atypical antipsychotic initiation. RESULTS: In the 12 months following atypical antipsychotic initiation, there were no statistically significant changes in metabolic parameters. Mean Hgb A1c increased from 6.9% to 7.2% (P = .47), mean systolic blood pressure decreased slightly from 132 to 127.8 mm Hg (P = .97), mean diastolic blood pressure decreased slightly from 79.6 to 76.6 mm Hg (P = .19), and mean LDL remained unchanged at 104.4 mg/dL (P = .92). Medications to control cardiometabolic disease increased substantially following atypical antipsychotic initiation; 35.1%, 39.2%, and 39.2% of patients were started on one or more new antihyperglycemics, antihypertensives, and statins, respectively. DISCUSSION: Patients had a significant increase in prescriptions to manage cardiometabolic disease in the 12 months following initiation of an atypical antipsychotic. Although medications to manage cardiometabolic disease increased, the actual metabolic parameters did not significantly change during the same time period.
RESUMO
Intravascular catheterization access for injection and sampling is one of the most common experimental surgical procedures. The vascular access port (VAP) was developed as an alternative to externalization of catheters. A VAP typically is implanted subcutaneously, with an attached catheter that is tunneled to a blood vessel for chronic catheterization. Catheters and ports have been designed to reduce the problems of occlusion, venous thrombosis, and infection. Key issues involve the use of meticulous aseptic technique for implantation of the devices and a "locking" solution that prevents clotting and retention of residues within the catheter. There are species-specific differences to be considered when planning the surgical implantation and maintenance of these devices. This manuscript reviews the procedures that have been used in the implantation of VAPs in large animal species and makes recommendations for procedures that will decrease complication rates associated with long-term catheterization.